ASH 2016: Hemato-oncologie Journaal 2


December 15, 2016

  • Deel deze pagina:

Het tweede journaal brengt u het laatste nieuws op het gebied van CML en AML. In de studietuin ziet u twee studies over autonome B-cel activatie bij NHL.


Gasten:

  • Dr. Peter Westerweel, Albert Schweitzer Ziekenhuis Dordrecht
  • Prof. dr. Hendrik Veelken, LUMC Leiden


Presentatie: Inge Diepman


Onderwerpen:

TKI stopstudies

  • 787 Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski TrialClinically Relevant Abstract
  • 788 Second TKI Discontinuation in CML Patients That Failed First Discontinuation and Subsequently Regained Deep Molecular Response after TKI Re-Challenge
  • 790 Discontinuation of Nilotinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Deep Molecular Responses for at Least 2 Years: A Multicenter Phase 2 Stop Nilotinib (Nilst) Trial
  • 791 Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial)


ABL001

  • 625 Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy
  • 1121 A Low Concentration of ABL001 Potentiates In Vitro TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells


SWOG S1203

  • 901 SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)


Venetoclax + LDAC

  • 102 Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia


CD 26 expressie

RR patienten

  • 341 Phase II Results of Ara-C and Idarubicin in Combination with the Selective Inhibitor of Nuclear Export (SINE) Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AML
  • 1069 Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)


Studietuin: Marvyn Koning, BSc.

  • 778 Antigen-Independent, Autonomous B-Cell Receptor Signaling As a Dominant Candidate Oncogenic Mechanism in ABC DLBCL
  • 4136 The B-Cell Receptor of Primary Cutaneous Follicle Center Lymphoma: Implications for Pathogenesis


Dit programma wordt financieel mogelijk gemaakt door Novartis, BMS en Janssen.

Gerelateerde artikelen